Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: A pilot study

被引：5

作者：

Cameron M. ^{[1
]}

Kersten C. ^{[1
]}

Van Helvoirt R. ^{[1
]}

Rohde G. ^{[2
]}

Fosså S. ^{[3
]}

Vistad I. ^{[4
]}

机构：

[1] Center for Cancer Treatment, Sørlandet Hospital Trust, 4604 Kristiansand

[2] Research Unit, Faculty of Health and Sport Sciences, University of Agder, Kristiansand

[3] Oslo University Hospital, Norwegian Radium Hospital, University of Oslo, Oslo

[4] Department of Gynaecology, Sørlandet Hospital Trust, Kristiansand

来源：

BMC Research Notes | / 4卷 / 1期

关键词：

Bladder Cancer; Palliative Radiation; Cancer Module; Existential Question; Radiation Therapist;

D O I：

10.1186/1756-0500-4-252

中图分类号：

学科分类号：

摘要：

Background: There is limited high-quality research investigating the efficacy of palliative radiation (PPR) with regard to symptoms and quality of life (QOL) among cancer patients with pelvic soft tissue tumors. As a result, clinicians are left with mainly retrospective studies, without reliable data on which to base treatment decisions. As a first step of a subsequent analysis of PPR's efficacy, we aimed to determine whether it is feasible to prospectively measure symptoms and QOL among patients treated with PPR. A secondary aim was to explore patients' willingness to answer existential questions in the setting of palliative pelvic radiation. Methods. Patients referred for palliative radiation of soft-tissue pelvic tumors were invited to enter the study. Symptoms were scored by study physicians and QOL was assessed by the EORTC QLQ C-30 questionnaire and site specific modules (PR25, CR38 or BL24) prior to start of radiation and 6 and 12 weeks after its completion. In addition, patients answered existential questions at each of the study visits. A radiation therapist was available to participants in order to answer their questions and ensure that questionnaires were completed. Findings. Five female and 17 male patients with prostate cancer (14), colorectal cancer (5) and bladder cancer (3) were included in the study. The median age of the participants was 75 years (range 62-90). Twenty patients were still in the study at the 6-week follow-up and 18 patients at the 12-week follow-up. Twenty-one patients had valid responses within all the EORTC QLQ C-30 scales at baseline, 20/20 at the 6-week follow-up and at the 12-week follow-up 17/18 patients still in the study had valid responses within all scales. This level of response was similar in the site-specific modules and among the existential questions. Discussion. Among patients with prostate, colorectal and bladder cancer, compliance to questionnaires assessing symptoms, QOL and existential questions 6 and 12 weeks after PPR is sufficient to enable evaluation in a larger and more homogeneous patient group in order to reach clinically valid conclusions as to the efficacy of PPR. © 2011 Cameron et al. licensee BioMed Central Ltd.

引用

共 28 条

[1]

Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., GLOBOCAN 2008 Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [Internet], International Agency for Research on Cancer, (2010)

[2]

Jemal, Et al., Global patterns of cancer incidence and mortality rates and trends, Cancer Epidemiol Biomarkers Prev, 19, 8, pp. 1893-907, (2010)

[3]

Cancer in Norway 2008 - Cancer incidence, mortality, survival and prevalence in Norway, Oslo: Cancer Registry of Norway, (2009)

[4]

Hoegler D., Radiotherapy for palliation of symptoms in incurable cancer, Curr Probl Cancer, 21, 3, pp. 129-83, (1997)

[5]

Konski A., Feigenberg S., Chow E., Palliative radiation therapy, Seminars in Oncology, 32, 2, pp. 156-164, (2005)

[6]

Denmeade S.R., Isaacs J.T., A history of prostate cancer treatment, Nature Reviews Cancer, 2, 5, pp. 389-396, (2002)

[7]

Smith S.C., Koh W.J., Palliative radiation therapy for gynaecological malignancies, Best Pract Res Clin Obstet Gynaecol, 15, 2, pp. 265-78, (2001)

[8]

Vistad I.C., Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians' assessments agree with those of their patients?, Int J Radiat Oncol Biol Phys, 171, 5, pp. 1335-42, (2008)

[9]

Widmark A.F., A systematic overview of radiation therapy effects in urinary bladder cancer, Acta Oncol, 42, 5-6, pp. 567-81, (2003)

[10]

Duchesne G.M., Bolger J.J., Griffiths G.O., Trevor Roberts J., Graham J.D., Hoskin P.J., Fossa S.D., Uscinska B.M., Parmar M.K.B., A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of medical research council trial BA09, International Journal of Radiation Oncology Biology Physics, 47, 2, pp. 379-388, (2000)

← 1 2 3 →